Welcome to our dedicated page for Black Diamond Therapeutics news (Ticker: BDTX), a resource for investors and traders seeking the latest updates and insights on Black Diamond Therapeutics stock.
Black Diamond Therapeutics, Inc. (NASDAQ: BDTX) is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in cancer. The company’s news flow centers on the development of its lead program, silevertinib (also known as BDTX-1535), a brain-penetrant fourth-generation EGFR MasterKey inhibitor being studied in EGFR-mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM).
On this page, readers can follow company announcements related to clinical trial progress, including Phase 2 data updates in frontline NSCLC patients with non-classical EGFR mutations and investigator-sponsored studies in EGFR-altered GBM. Black Diamond’s releases describe objective response rates, CNS activity, duration of treatment or response, and plans for randomized Phase 2 trials in newly diagnosed GBM patients.
News items also cover corporate and financial updates, such as quarterly and annual financial results, cash runway commentary, and strategic priorities around advancing silevertinib. In addition, Black Diamond reports on business development activities, including a global licensing agreement with Servier for BDTX-4933, a Phase 1 therapy designed to target RAF/RAS-mutant solid tumors.
Investors and observers can use this news feed to track webcast and conference presentations, regulatory and development plans in NSCLC and GBM, and partnership discussions around pivotal development. Regular updates provide insight into how Black Diamond Therapeutics is progressing its MasterKey therapies across genetically defined tumor types and CNS-involved disease.
Black Diamond Therapeutics (Nasdaq: BDTX) reported Q1 2020 financials, highlighting $357.2 million in cash and equivalents. The initial public offering in February raised $231.3 million, bolstering their position to fund operations through 2023. The Phase 1/2 clinical trial for BDTX-189, their lead therapy, is ongoing, with completion expected in the first half of 2021. Operating expenses have increased, with R&D expenses at $7.4 million and G&A expenses at $5.5 million due to increased personnel and public company costs. The net loss for the quarter was $12.1 million, reflecting continued investment in clinical development.
Black Diamond Therapeutics (Nasdaq: BDTX) announced that its CEO, David M. Epstein, Ph.D., will present a business update at the Bank of America Global Research Health Care Conference 2020. The presentation is scheduled for May 12, 2020, at 4:20 PM ET. Black Diamond is focused on developing small molecule, tumor-agnostic therapies targeting undrugged mutations in genetically defined cancers. Their proprietary Mutation-Allostery-Pharmacology (MAP) platform enables the analysis of genetic data to create therapies for specific mutation families.